Use Of 5α-Reductase Inhibitors And Survival Of Esophageal And Gastric Cancer In A Nationwide Swedish Cohort Study

    May 2023 in “ Acta Oncologica
    Sirus Rabbani, Fredrik Mattsson, Jesper Lagergren, Shao‐Hua Xie
    TLDR 5α-reductase inhibitors do not improve survival in oesophageal and gastric cancer patients.
    This nationwide Swedish cohort study investigated whether the use of 5α-reductase inhibitors (5-ARIs) improves survival in men who underwent surgery for oesophageal or gastric cancer. The study included 1,769 patients, of whom 64 (3.6%) were users of 5-ARIs. The results showed that users of 5-ARIs did not have a decreased risk of 5-year all-cause mortality (adjusted HR 1.13, 95% CI 0.79-1.63) or 5-year disease-specific mortality (adjusted HR 1.10, 95% CI 0.79-1.52) compared to non-users. Subgroup analyses also showed no association between 5-ARIs use and decreased mortality risk. The study concluded that 5-ARIs do not improve survival after curative treatment for oesophago-gastric cancer.
    Discuss this study in the Community →

    Research cited in this study

    3 / 3 results